The responses of 14 hyperlipidemic subjects to 4 hypolipidemic agents were compared by measureing cholesterol and triglyceride in whole plasma, very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) monthly for 2 months before and 3 months during treatment with each of 4 drugs: clofibrate, 2 g/d; colestipol, 20 g/d; para-aminosalicylic acid-ascorbate (PAS-C), 6–8 g/d; and oxandrolone, 7.5 mg/d. Lipid responses proved to be stable by the first monthly evaluation both off and on each drug. Mean adherence was high and similar for all agents (81–92% of the prescribed dose). Clofibrate was associated with significant decreases in mean plasma cholesterol (−16%, p<.01), plasma triglyceride (−51%, p<.005), VLDL-cholesterol (−61%, p<.005) and VLDL-triglyceride (−61%, P<.005), while HDL cholesterol increased (+20%, p<.01), and the LDL-cholesterol/HDL ratio declined (−24%, p<.05). Colestipol was associated with decreases in mean plasma cholesterol (−15%, p<.01) and LDL-cholesterol (−22%, p<.05), while VLDL-triglyceride increased (+41%, p<.05), and the LDL-cholesterol/HDL-cholesterol ratio declined (−25%, p<.05). PAS-C was associated with decreases in VLDL-cholesterol (−30%, p<.05), and VLDL-triglyceride (−29%, p<.05), while the LDL-cholesterol/HDL-cholesterol ratio remained unchanged. Oxandrolone was associated with increases in mean plasma cholesterol (+7%, p<.05), LDL-cholesterol (+45%, p<.005 [+25% excluding one subject who increased 298%]), and LDL-triglyceride (+24%, p<.01), while decreases occurred in plasma triglyceride (−31%, p<.05), VLDL-cholesterol (−26%, p<.05), VLDL-triglyceride (−42%, p<.005), HDL-cholesterol (−45%, p<.005), and HDL-triglyceride (−43%, p<.01). The mean LDL-cholesterol/HDL-cholesterol ratio increased by 109% (p<.005), reflecting the reciprocal changes in LDL and HDL. Thus, while both clofibrate and colestipol were associated with significant, equivalent reductions in theoretical atherogenic risk, oxandrolone produced a net effect that was not only adverse but 4 times that magnitude, suggesting caution in its long-term use, even for the management of hypertriglyceridemia.
KeywordsHigh Density Lipoprotein Clofibrate Colestipol Lipid Research Clinic Oxandrolone
Unable to display preview. Download preview PDF.
- 7.Lipid Research Clinics Program Manual of Laboratory Operations, (1974) Vol. 1, Lipid and Lipoprotein Analysis, Washington, D.C., US Government Printing Office, DHEW Pub No 75-628.Google Scholar
- 8.Winer, B.J. (1962) in Statistical Principles in Experimental Design, McGraw-Hill Book Company, New York, Chapter 7.Google Scholar
- 9.Marascuilo, L.A., and McSweeney, M. (1977) in Nonparametric and Distribution-free Methods for the Social Sciences, pp. 176, Brooks/Cole Publishing Co.Google Scholar
- 17.Zannis, V.I., Just, P.W., and Breslow, J.L. (1981) Am. J. Hum. Genet. 3, 11–24.Google Scholar
- 23.Boman, H., Hazzard, W.R., Albers, J.J., Cooper, M.N., and Motulsky, A.G. (1975) Am. J. Human Genet. 27, 19A.Google Scholar
- 24.Oliver, M.R., Heady, J.A., Morris, J.N., and Cooper, J. (1978) Br. Heart J. 40, 1069–1179.Google Scholar
- 26.Brunzell, J.D., and Bierman, E.L. (1982) Med. Clin, N. Am. 66, 455–468.Google Scholar